In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.
DV-7751a is an investigational fluoroquinolone with improved spectrum and potency against gram-positive bacteria. We studied the in vitro activity of this compound against 771 recent clinical isolates by the reference agar and broth microdilution methods. Its activity was compared with those of ciprofloxacin, levofloxacin, and ofloxacin and with those of ceftazidime, oxacillin, and gentamicin where relevant. DV-7751a was four- to eightfold more active than the comparison fluoroquinolones against Enterococcus spp. (including vancomycin-resistant strains), Staphylococcus spp. (including oxacillin-resistant Staphylococcus aureus), Streptococcus spp., other gram-positive pathogens, and some anaerobes. The DV-7751a activity against most gram-negative species was similar to that of ofloxacin and ciprofloxacin. DV-7751a appears to be a candidate for the therapy of some mixed-flora infections and the treatment of bacteria resistant to the current fluoroquinolones.
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001420:Bacteria, Aerobic / Q000187:drug effects*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D024841:Fluoroquinolones; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C084755:DV 7751a